Long QT syndrome (LQTS) is a myocardial repolarisation disorder characterised by prolongation of the QT interval on the surface electrocardiogram (ECG). The clinical presentation of LQTS consists of palpitations, syncope, seizures, and sudden cardiac death due to a characteristic arrhythmia known as *torsades de pointes* (TdP) ([@bib10]; [@bib17]; [@bib23]).

The QT interval represents the total duration of ventricular depolarisation and repolarisation. It is measured on the ECG from the first deflection of the QRS complex to the end of the T-wave. Prolongation of the QT interval usually results from delayed repolarisation. This can be caused by drugs or inherited ion channel abnormalities, which block or result in loss of function of potassium channels (IKr, IKs, and IKl), or opening or gain of function of sodium (Ina) or calcium channels ([@bib11]). The QT interval is usually corrected for heart rate, leading to the corrected QT interval QTc.

Several factors such as gender, age, electrolyte disturbances, cardiovascular diseases (CVD), and different types of drugs can affect the duration of the QT interval ([@bib24]; [@bib2]). Due to the risk of fatal arrhythmias, the US Food and Drug Administration (FDA) now requires thorough studies to evaluate the potency of new drugs to induce QT-interval prolongation in preclinical and early phase I clinical trials in healthy individuals ([@bib10]). However, for new anticancer drugs these studies are usually not performed in healthy individuals because of their toxicity profile ([@bib5]; [@bib6]).

As with many drugs, tyrosine kinase inhibitors (TKIs) are reported to prolong the QT interval ([@bib21]; [@bib1]; [@bib14]; [@bib22]; [@bib7]; [@bib8]; [@bib9]; [@bib12]; [@bib20]). *In vitro* studies demonstrated that lapatinib and imatinib interact with the phosphorylation of the cardiac hERG channel. This results in a reduction of the repolarising current (IKr), which can lead to action potential prolongation and subsequent QT-interval prolongation ([@bib14]; [@bib9]).

In a small prospective clinical study to evaluate the cardiac safety of lapatinib in 21 patients, a mean QTc increase of 8.63 ms was seen ([@bib7]). In three prospective post-marketing studies in patients with solid tumours treated with sorafenib (*N=*31), pazopanib (*N=*48), and sunitinib (*N=*24) a modest increase of 9.0 ms of QTc interval with the use of sorafenib, 4.4 ms after start of pazopanib and 9.6 ms after start of sunitinib was seen ([@bib1]; [@bib22]; [@bib12]).

These drugs have been approved by the FDA because they appear highly effective in situations where treatment options are limited. With an increasing number of TKIs on market, a relatively long on-treatment time, and the application in the adjuvant setting, which is already standard for imatinib in patients with localised GIST with a high risk of relapse, and which is being explored for other TKIs in various tumour types, thorough QTc studies in this group of drugs are necessary to get more insight into their cardiac safety. In this multicentre study performed in four centres in the Netherlands and Italy, we describe the incidence and relevance of QTc-interval prolongation in patients with cancer treated with different types of TKIs.

Patients and methods
====================

Study design
------------

We undertook a retrospective study in patients with solid malignancies, who were treated with any type of TKI. Patients from four centres in the Netherlands (Erasmus MC Cancer Institute, Rotterdam, Leiden University Medical Centre, Leiden, and Netherlands Cancer Institute---Antoni van Leeuwenhoek, Amsterdam) and Italy (Salvatore Maugeri Foundation, Pavia) were included.

This study was reviewed and approved by the Erasmus MC Medical Ethical Board (MEC 2013-148). All ECGs were obtained as standard clinical care. Demographic and clinical characteristics of the analysed cohort were collected using clinical record forms designed for this study.

Patients were considered eligible if they were aged ⩾18 years, were treated for solid tumours with any type of TKI and if at least one ECG before start of TKI treatment and one ECG during treatment with TKI were available. Exclusion criteria were as follows: ECGs that do not match criteria for accurate QTc-interval measurements (intra-ventricular conduction delay and/or pacemaker driven rhythm), missing ECGs at baseline or during therapy, and patients with a time-lapse between baseline ECG and start of TKI treatment of more than 1 year. Patients who were subsequently treated with different TKIs were included once. All standard 12-lead ECGs analysed in this study were reviewed by a single expert cardiologist (CN). The QT interval was measured from the beginning of the QRS complex until the point where the deflection of the T wave crosses the iso-electric line. A description of the statistical method is presented in the [Supplementary Material](#sup1){ref-type="supplementary-material"}.

Definition of QTc prolongation
------------------------------

Since increases in heart rate result in shortening of the QT interval, a correction for heart rate was applied using the Bazett formula ([@bib19]):

In this formula, RR is the interval between two subsequent R waves. The Bazett formula is the most frequently applied correction in clinical practice, leading to the corrected QT interval or QTc interval ([@bib19]).

A prolonged QT interval is associated with an increased risk of polymorphic ventricular tachycardia, torsade de pointes (TdP). This study defined a prolonged QT interval corrected for heart rate (QTc) as ⩾470 ms, which represents \<0.5% of the healthy population ([@bib13]) and has been shown to be associated with an increased risk of TdP ([@bib23]). A clinically relevant increase in QTc (ΔQTc) was defined as an increase of ⩾30 ms between a patient\'s baseline and subsequent ECG as this has also been shown to be associated with increased risk ([@bib15]). The QTc was also categorised according to the [@bib4] (grade 0, QTc\<450; grade 1, QTc 450--479 ms; grade 2, QTc 480--499 ms; grade 3, QTc⩾500 ms; grade 4, QTc⩾500 ms with life-threatening signs or symptoms; grade 5, death). Relevant CVD was defined as myocardial infarction and/or heart failure.

Outcome measures used in this study were (*i*) the quantitative difference in QTc interval between on therapy and baseline ECG measurements (ΔQTc, ms), (*ii*) the transition from a condition of normal repolarisation to a condition in which QTc is prolonged to an extent with high risk of arrhythmia as a consequence of the TKI therapy (*i.e.*, from QTc\<470 to QTc⩾470 ms) ([@bib13]; [@bib23]), (*iii*) clinically relevant ΔQTc (defined as ΔQTc⩾30 ms, above which the risk for TdP is significantly increased) ([@bib15]) and (*iv*) QTc-interval CTCAE grade increase during TKI therapy.

Results
=======

Patient characteristics
-----------------------

A total of 1933 cases of TKI use were screened in this study. In 644 cases at least one ECG before treatment and one ECG during treatment were available. Among these cases, 18 patients were included twice, with subsequent use of different TKIs. One patient had a pacemaker-driven rhythm. In 262 patients, the time lapse between baseline ECG and start of treatment was more than 1 year and patients were therefore excluded from the analysis. The remaining study cohort consisted of 363 patients. The median age at start of treatment was 60 years (interquartile range (IQR) 51--67), and 59% of patients were male. Sunitinib was the most frequently used TKI in our study cohort, with a total of 110 treated patients. The median QTc interval at baseline visit was 401 ms (IQR 388--415), where 346 patients (95.3%) had a normal QTc interval (CTCAE grade 0), 14 (3.9%) had grade 1, 2 patients (0.6%) had grade 2, and 1 patient (0.3%) had a grade 3 QTc interval. A total number of 37 patients (10.2%) had a known history of relevant CVD, while 34 patients (9.4%) used co-medication, that can lead to QTc-interval prolongation ([@bib21]). Patients\' demographics and disease characteristics are presented in [Table 1](#tbl1){ref-type="table"}.

Variables modulating QTc interval at baseline visit
---------------------------------------------------

At baseline measurements, QTc was slightly, but significantly greater in females than in males (QTc~females~=404 ms (IQR 392--417) *vs* QTc~males~=399 ms (IQR 385--414), *P=*0.027), which is consistent with previous studies ([@bib21]). Patients treated with co-medication known to prolong the QTc interval, such as anti-depressants, anti-epileptics, and anti-emetics, had a statistically significant higher baseline QTc interval than the patients who did not use such co-medication (409 ms (IQR 398--424) *vs* 400 ms (IQR 387--414), respectively, *P=*0.035). Consistent with previous studies, patients suffering from hypokalaemia had longer median QTc intervals than patients with normokalaemia and hyperkalaemia (median QTc in hypokalaemic, normokalaemic, and hyperkalaemic patients 416 ms (IQR 376--431), 401 ms (IQR 389--415), and 391 ms (IQR 381--408), *P=*0.028, respectively). A more detailed report about baseline QTc intervals according to the evaluated variables is found in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

Quantitative variations of the QTc interval
-------------------------------------------

The median on treatment time before the ECG was performed was 43 days (IQR 26--118 days). In the entire population of 363 patients, the start of a TKI resulted in a statistically significant increase in QTc interval, with a median ΔQTc of +11 ms (*P\<*0.00001). The distribution of ΔQTc was significantly different across TKIs (*P=*0.0001). When analysing subgroups of patients treated with specific TKIs, patients treated with sunitinib (*N=*110), vemurafenib (*N=*67), sorafenib (*N=*52), imatinib (*N=*41), and erlotinib (*N=*21) showed a statistically significant increase in QTc interval after start of treatment (median ΔQTc ranging from +7 to +24 ms, *P\<*0.004; [Figure 1](#fig1){ref-type="fig"}). For lapatinib (*N=*16) and pazopanib (*N=*46), no statistically significant increase in QTc interval after start of treatment was found ([Table 2](#tbl2){ref-type="table"}).

Increase in CTCAE grade and prevalence of high-risk patients
------------------------------------------------------------

A statistically significant increase in CTCAE grade for QTc intervals was observed after start of TKI therapy in the whole cohort (*P=*0.0003). In detail, 33 patients (9.1%) were characterised by an increased CTCAE grade. Of these, 31 passed from grade 0 to grade⩾1, while the remaining 2 individuals passed from grade 1 to grade 2 or 3. Of the remaining patients, 321 (88.4%) did not have an increase or decrease in CTCAE grade after start of TKI treatment, while 9 patients (2.5%) had a reduced CTCAE grade for QTc interval ([Table 3](#tbl3){ref-type="table"}).

Similarly, a statistically significant increase in the prevalence of high-risk patients was observed after TKI therapy start (QTc~baseline~⩾470 ms=1.7% *vs* QTc~therapy~⩾470 ms=5.8%, *P=*0.005), with 20 individuals (5.5%) who transitioned from a low-risk to a high-risk condition. Moreover, 5 patients (1.4%) developed QTc⩾500 ms (CTCAE grade 3) after therapy start, and 76 patients (20.9%) experienced a clinically relevant QTc increase after TKI start. All five patients who developed QTc⩾500 ms after start of therapy had a ΔQTc of ⩾100 ms.

When focusing on specific TKI subgroups, we observed that individuals treated with vemurafenib (*N=*67) were characterised by a statistically significant increase both in terms of CTCAE grade for QTc intervals (*P=*0.008) and in the probability of becoming high-risk patients (*P=*0.023), also showing the greatest probability of clinically relevant QTc increase (34.3%). No statistically significant variations in the evaluated outcomes were observed in the other TKI subgroups.

Characterisation of TKI-induced QTc variability
-----------------------------------------------

The median age of patients who had a worsening of the CTCAE grade for QTc interval was significantly higher than that of patients who did not (62 years (IQR 59--72) *vs* 60 years (IQR 51--67), respectively, *P=*0.023). These patients also more often suffered from hypokalaemia (20.7% *vs* 3.1%, *P=*0.0009; [Table 4](#tbl4){ref-type="table"}). Multivariate logistic regression confirmed that age and hypokalaemia were independent predictors of worsened CTCAE grade for QTc interval (OR=1.10, 95% CI=1.05--1.16, *P=*0.0002 and OR=10.30, 95% CI=2.22--4.64, *P=*0.002).

Similarly, patients who had QTc prolongation to ⩾470 ms after start of TKI treatment were significantly older than patients who did not (66 years (IQR 60--76) and 60 years (IQR 51--66), respectively, *P=*0.007) and were more frequently treated with QTc-prolonging co-medication (25% *vs* 8.5%, *P=*0.030). This was confirmed by multivariate logistic regression (OR=1.10, 95% CI=1.04--1.15, *P=*0.0004 and OR=4.38, 95% CI=1.14--15.25, *P=*0.023).

We did not identify variables that have a statistically significant impact on quantitative ΔQTc or on the probability of clinically relevant ΔQTc ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}).

Discussion
==========

We found a significant increase in QTc intervals after start of treatment with sunitinib, vemurafenib, sorafenib, imatinib, and erlotinib. In most cases, the increase in QTc interval is only modest and under normal conditions not clinically relevant. However, in 76 of the 363 patients the start of TKI treatment resulted in a clinically relevant increase of the QTc interval of ⩾30 ms. The incidence of high-risk patients, defined as QTc⩾470 ms ([@bib23]), increased during treatment with a TKI. Still, only the subgroup receiving vemurafenib showed a statistically significant increase in the number of patients with QTc\>470 ms.

In the entire cohort, 21% of patients showed a clinically relevant increase in QTc of ⩾30 ms with TKI treatment, but as most had a normal baseline QTc interval, only 5% had a QTc of ⩾470 ms, which is associated with increased risk of arrhythmias. Although older patients, patients with low potassium and patients taking co-medication which can prolong the QTc interval are at higher risk of QTc-interval prolongation, it is still not possible to differentiate which patient is at risk at the start of treatment.

Therefore, treating physicians should anticipate this possible increase in QTc intervals and perform ECGs during treatment with TKI, and be aware of symptoms, such as palpitation, seizures, and collapse, which may be the result of drug-induced LQTS. In those diseases where alternative treatment is available, such as in metastatic renal cell carcinoma where sunitinib and pazopanib have equivalent efficacy ([@bib18]), consideration should be given to use a TKI with less QTc prolongation effects if the QTc is prolonged at baseline or develops during treatment.

Furthermore, many patients use co-medication during TKI treatment. As drugs of a broad variety are known for drug-induced QTc-interval prolongation, it is likely that patients use several drugs which can lead to QTc-interval prolongation and thereby intensifying the effect on the QTc interval. This was shown in this study, where 14 patients (4%) using such co-medication were more likely to develop QTc prolongation. In those cases, extra awareness may be necessary and switching to drugs that are not likely to have an effect on QTc interval should be considered.

This study has several limitations. This was a retrospective study in patients treated with cancer, and therefore in most cases ECGs were not performed at predefined times before, during, and after TKI therapy. Since fluctuations in QTc interval are frequent and may be caused by many factors ([@bib24]; [@bib2]), this is a weakness of our study, and may have influenced outcome ([@bib16]). Also, only patients treated with a TKI were included and there was no control group given non-TKI treatment in which the variation in the QTc interval could be examined. Furthermore, there may be a bias in patient selection since patients with cardiac events may be more likely to have had ECGs performed. Patients who died from arrhythmia may not have been included in analyses when no ECGs were available. One patient taking a TKI in the study died suddenly. This did not occur in a hospital and no cause of death was reported so it is unknown whether this was related to QTc-interval prolongation. Possible effects from electrolyte disorders on the QTc interval may have been missed, because of missing data. However, we showed in a large group of patients treated with TKIs that there is an overall increase in QTc interval after start of treatment, which may possibly be harmful for patients treated with these drugs. Future prospective studies could improve the current knowledge about TKI-induced QTc prolongation.

Overall, we may conclude that most TKIs tend to cause an increase in QTc intervals. In some cases, this increase is clinically relevant, and therefore the QTc interval should be verified in patients before starting TKI treatment and during therapy. Monitoring QTc intervals during TKI treatment is particularly important in patients with a history of QTc-interval prolongation, in patients using co-medication which can prolong the QTc interval, in patients with electrolyte disorders, and in patients with pre-existing CVD. Furthermore, during treatment with TKIs physicians should be aware of clinical symptoms, which may be attributed to QTc-interval prolongation.

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
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![**ΔQTc in the whole cohort and in specific TKIs.** Blue bars represent the median baseline QTc interval and red bars represent the median QTc interval during treatment. At the y axis, the QTc interval is expressed in ms.](bjc201582f1){#fig1}

###### Patient characteristics

  **Variable**            **N (%) or median (IQR)**
  ----------------------- ---------------------------
  **Gender**              
  Male                    215 (59)
  Female                  148 (41)
  Age (years)             60 (51--67)
  QTc-interval baseline   401 (388--415)
  QTc-interval therapy    415 (397--431)
  **Tumour type**         
  RCC                     101 (27.8)
  GIST                    49 (13.5)
  HCC                     45 (12.4)
  Lung cancer             27 (7.4)
  Breast cancer           16 (4.4)
  Melanoma                69 (19.0)
  Other                   56 (15.4)
  **Type of TKI**         
  Sunitinib               110 (30.3)
  Vemurafenib             67 (18.5)
  Sorafenib               52 (14.3)
  Pazopanib               46 (12.7)
  Imatinib                41 (11.3)
  Erlotinib               21 (5.8)
  Lapatinib               16 (4.4)
  Gefitinib               10 (2.8)
  **WHO PS baseline**     
  0                       155 (42.7)
  1                       195 (53.7)
  2                       12 (3.3)
  3                       1 (0.3)
  CVD                     37 (10.2)
  QTc co-medications      34 (9.4)
  **Race**                
  Caucasian               349 (96.1)
  Other                   14 (3.5)
  **Site**                
  EMC                     184 (50.7)
  NKI                     118 (32.5)
  LUMC                    54 (14.9)
  SMF                     7 (1.9)

Abbreviations: CVD=cardiovascular disease; EMC=Erasmus MC---Cancer Institute; GIST=gastro-intestinal stromal tumour; HCC=hepatocellular carcinoma; LUMC=Leiden University Medical Centre; NKI=Netherlands Cancer Institute---Antoni van Leeuwenhoek; RCC=renal cell cancer; SMF=Salvatore Maugeri Foundation; TKI=tyrosine kinase inhibitor; WHO PS=World Health Organisation performance score.

###### TKI-induced change in QTc interval

                      **QTc interval (ms)** **Median (IQR)**                    
  ------------- ----- ---------------------------------------- ---------------- ---------------
  Whole         363   401 (388--415)                           415 (397--431)   **\<0.00001**
  Sunitinib     110   393 (380--410)                           406 (390--424)   **\<0.00001**
  Vemurafenib   67    401 (394--417)                           427 (415--442)   **\<0.00001**
  Sorafenib     52    400 (386--412)                           410 (394--425)   **0.0004**
  Pazopanib     46    402 (390--411)                           412 (395--431)   0.079
  Imatinib      41    410 (396--424)                           425 (410--439)   **0.002**
  Erlotinib     21    412 (398--430)                           421 (414--440)   **0.004**
  Lapatinib     16    413 (405--423)                           414 (397--428)   0.982
  Gefitinib     10    403 (396--417)                           409 (390--429)   0.919

Abbreviations: IQR=interquartile range; n=number of patients within each TKI group; ΔQTc=median difference between QTc interval during TKI treatment and QTc interval at baseline; TKI=tyrosine kinase inhibitor. Bold values are statistically significant.

###### Increase in CTCAE grade and prevalence of high-risk patients

                                  **Change in CTCAE Grade after start of therapy**   **QTc**⩾**470**                                                
  ------------- ----- ----------- -------------------------------------------------- ----------------- ---------- ------------ --------- ---------- -----------
  Whole         363   76 (20.9)   33 (9.1)                                           321 (88.4)        9 (2.5)    **0.0003**   6 (1.7)   21 (5.8)   **0.005**
  Sunitinib     110   22 (20.0)   4 (3.6)                                            104 (95.6)        2 (1.8)    0.746        1 (0.9)   3 (2.7)    0.617
  Vemurafenib   67    23 (34.3)   9 (13.4)                                           58 (86.6)         0 (0)      **0.008**    1 (1.5)   8 (11.9)   **0.023**
  Sorafenib     52    11 (21.2)   6 (11.6)                                           45 (86.6)         1 (1.9)    0.073        1 (1.9)   2 (3.9)    1
  Pazopanib     46    6 (13.0)    3 (6.5)                                            41 (89.1)         2 (4.4)    0.410        1 (2.2)   2 (4.4)    1
  Imatinib      41    8 (19.5)    5 (12.2)                                           34 (82.9)         2 (4.9)    0.430        1 (2.4)   1 (2.4)    1
  Erlotinib     21    3 (14.3)    3 (14.3)                                           18 (85.7)         0 (0)      0.174        0 (0)     2 (9.5)    NA
  Lapatinib     16    1 (6.3)     1 (6.3)                                            14 (87.5)         1 (6.3)    1            1 (6.3)   1 (6.3)    1
  Gefitinib     10    2 (20.0)    2 (20.0)                                           7 (70.0)          1 (10.0)   0.423        0 (0)     2 (20.0)   NA

Abbreviations: CTCAE=common terminology criteria for adverse events; *N*=number of patients; NA=not applicable; TKI=tyrosine kinase inhibitor; ΔQTc=difference between QTc interval during TKI treatment and QTc interval at baseline measurement. Bold values are statistically significant.

###### Variables influencing CTCAE grade for QTc interval and the probability to become a high-risk patient

                            **CTCAE grade during TKI**   **Transition to high risk (QTc**⩾**470 ms)**                                            
  ------------------- ----- ---------------------------- ---------------------------------------------- ------------ ------------- ------------- -----------
  Age (years)         363   62 (59--72)                  60 (51--67)                                    **0.026**    66 (60--76)   60 (51--66)   **0.007**
  **Gender**                                                                                                                                     
  Males               215   22 (66.7)                    193 (58.5)                                     0.458        14 (70)       201 (58.6)    0.358
  Females             148   11 (33.3)                    137 (41.5)                                                  6 (30)        142 (41.4)     
  **Co-medication**                                                                                                                              
  Yes                 34    6 (18.2)                     28 (8.5)                                       0.107        5 (25)        29 (8.4)      **0.030**
  No                  329   27 (81.8)                    302 (91.5)                                                  15 (75)       314 (91.6)     
  **CVD**                                                                                                                                        
  Yes                 37    5 (15.2)                     32 (9.7)                                       0.360        4 (20)        33 (9.6)      0.134
  No                  326   28 (84.9)                    298 (90.3)                                                  16 (80)       310 (90.4)     
  **DM**                                                                                                                                         
  Yes                 43    3 (9.1)                      40 (12.1)                                      0.782        1 (5)         42 (12.2)     0.489
  No                  320   30 (90.9)                    290 (87.9)                                                  19 (95)       301 (87.8)     
  **Ca**^**2+**^                                                                                                                                 
  Normo/Hyper         169   13 (61.9)                    156 (71.6)                                     0.451        8 (80)        161 (70.3)    0.728
  Hypo                70    8 (38.1)                     62 (28.4)                                                   2 (20)        68 (29.7)      
  **K**^**+**^                                                                                                                                   
  Normo/Hyper         304   23 (79.3)                    281 (96.9)                                     **0.0009**   16 (88.9)     288 (95.7)    0.204
  Hypo                15    6 (20.7)                     9 (3.1)                                                     2 (11.1)      13 (4.3)       

Abbreviations: Ca^2+^=calcium level at time of QTc measurement during treatment; CVD=cardiovascular disease; CTCAE, common terminology criteria for adverse events; DM=diabetes mellitus; IQR, interquartile range; K^+^, potassium level at time of QTc measurement during treatment; *N*, number of analysed patients with non-missing values; TKI, tyrosine kinase inhibitor. Bold values are statistically significant.

[^1]: These authors contributed equally to this work.
